NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
References
- Institute for Health Metrics and Evaluation. Global burden of disease compare. 2017.
https://vizhub.healthdata.org/gbd-compare/ . - Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34(35): 2746–51. DOI: 10.1093/eurheartj/eht280
- Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012; 142(6): 1489–98. DOI: 10.1378/chest.11-2888
- Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114(2): 119–25. DOI: 10.1161/CIRCULATIONAHA.105.595140
- Medicines Patent Pool. Exploring the expansion of the Medicines Patent Pool’s mandate to patented essential medicines. A feasibility study of the public health needs and potential impact. Geneva, CH: Medicines Patent Pool; 2018. 75.
https://medicinespatentpool.org/uploads/2018/05/Octo2018_Feasibility-Study-Expansion-of-the-MPP-Mandate-Appendix.pdf . - Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B et al. The World Heart Federation roadmap for nonvalvular atrial fibrillation. Global Heart. 2017; 12(4): 274.
https://www.world-heart-federation.org/cvd-roadmaps/whf-global-roadmaps/atrial-fibrillation/ . - Morillo C, Banerjee P, Wood D, Jouven X. Atrial Fibrillation: The Current Epidemic. Journal of Geriatric Cardiology. 2017; 14: 198–200.
- Chugh SS, Roth AR, Gillum RF, Mensah GA. Global Burden of Atrial Fibrillation in Developed and Developing Nations. Global Heart. 2014; 1: 113–119. DOI: 10.1016/j.gheart.2017.01.015
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857–67. DOI: 10.7326/0003-4819-146-12-200706190-00007
- Goel S, Sharma A. COVID-19 pandemic and its impact on cardiology and its subspecialty training. Prog Cardiovascu Dis; 2020. DOI: 10.1016/j.pcad.2020.05.004
- Krumholz HM. Where have all the heart attacks gone. Except for treating Covid-19, many hospitals seem to be eerily quiet. The New York Times. 2020.
https://www.nytimes.com/2020/04/06/well/live/coronavirus-doctors-hospitals-emergency-care-heart-attack-stroke.html . - European Society of Cardiology. Fear of COVID-19 keeping more than half of heart attack patients away from hospitals. European Society of Cardiology. 2020.
https://www.escardio.org/The-ESC/Press-Office/Press-releases/Fear-of-COVID-19-keeping-more-than-half-of-heart-attack-patients-away-from-hospitals . DOI: 10.1016/j.pcad.2020.05.004 - Barnes GD, Ageno W, Ansell J, Kaatz S. Recommendation on the nomenclature for oral <nticoagulants: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2015; 12(6): 1154–1156. DOI: 10.1111/jth.12969
- Karmacharya B, Adeoye A, Di Cesare M, Hakim F, Huffman MD, Katbeth A et al. Application for inclusion of non-vitamin K antagonists oral anticoagulant (NOACs) for the treatment of non-valvular atrial fibrillation in the WHO Model List of Essential Medicines. 2019.
https://www.who.int/selection_medicines/committees/expert/22/applications/s10.2_dabigatran.pdf?ua=1 . - Medicines Patent Pool. Exploring the expansion of the Medicines Patent Pool’s mandate to patented essential medicines. 66.
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–51. DOI: 10.1056/NEJMoa0905561
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–91. DOI: 10.1056/NEJMoa1009638
- Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981–92. DOI: 10.1056/NEJMoa1107039
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093–104. DOI: 10.1056/NEJMoa1310907
- Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016; 353: i3189. DOI: 10.1136/bmj.i3189
- Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362: k2505. DOI: 10.1136/bmj.k2505
- Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018; 20(3): 420–8. DOI: 10.1093/europace/euw416
- Neumann I, Schünemann HJ.
Application for inclusion of novel oral anticoagulants for the treatment of non-valvular atrial fibrillation in the who model list of essential medicines 2015 ; 2014. World Health Organization.https://www.who.int/selection_medicines/committees/expert/20/applications/NOACs/en/ . - World Health Organization. 20th Expert Committee on Selection and Use of Essential Medicines. Peer Review Report #2. Novel oral anticoagulants; 2015.
- World Health Organization. Report of the WHO Expert Committee on the Selection and Use of Essential Medicines; 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). WHO/MVP/EMP/IAU/2019.10. WHO Technical Report Series 248.
https://www.who.int/medicines/publications/essentialmedicines/UNEDITED_TRS_2019_EC22_Sept.pdf?ua=1 . - Neumann I, Schünemann HJ. Application to add Direct Oral Anticoagulants (DOAC) to WHO Model List of Essential Medicines as a medicine for treatment of non-valvular atrial fibrillation and treatment venous thromboembolism. 2018.
https://www.who.int/selection_medicines/committees/expert/22/applications/s10.2_DOACs.pdf?ua=1 . - Laing R, Waning B, Pharm AG, Ford F, Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. The Lancet. 2003; 361 (9370): 1723–1729.
https://www.sciencedirect.com/science/article/pii/S0140673603133752?via%3Dihub . DOI: 10.1016/S0140-6736(03)13375-2 - Persaud N, Jiang M, Shaikh R, Bali A, Oronsaye E, Woods H. Comparison of essential medicines lists in 137 countries. Bull. World Health Organ. 2019; 97: 394–404C.
https://www.who.int/bulletin/volumes/97/6/18-222448/en/ . - Bazargani YT, Ewen M, De Boer A, Leufkens HGM, Mantel-Teeuwisse AK. Essential medicines are more available than other medicines around the globe. PLOS One. 2014; 9(2):
e87576 .https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087576 . DOI: 10.1371/journal.pone.0087576 - Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. The Lancet. 2017; 389(10067): 403–76.
https://www.ncbi.nlm.nih.gov/pubmed/27832874 . DOI: 10.1016/S0140-6736(17)31209-6 - IMS Institute for Healthcare Informatics.
Understanding the role and use of essential medicines lists . Durham, NC, USA: IMS Institute; 2015. 16.http://apps.who.int/medicinedocs/documents/s21980en/s21980en.pdf . - Medicines Patent Pool. Exploring the expansion of the Medicines Patent Pool’s mandate to patented essential Medicines. 75.
https://medicinespatentpool.org/uploads/2020/04/Executive-Summary-Exploring-the-Expansion-of-the-Medicines-Patent-Pool%E2%80%99s-Mandate-to-Patented-Essential-Medicines-A-Feasibility-Study-of-the-Public-Health-Needs-and-Potential-Impact.pdf . - Simmons B, Cooke GS, Miraldo M. Effect of voluntary licenses for hepatitis C medicines on access to treatment: a difference-in-differences analysis. The Lancet Global Health. 2019; 7(9): e1189–e1196.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30266-9/fulltext . - Hoen FM, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016. Bull. World Health Organ. 2018; 96: 185–193.
https://www.who.int/bulletin/volumes/96/3/17-199364/en/ . DOI: 10.2471/BLT.17.199364 - World Heart Federation. Improving access to essential medicines for circulatory diseases. A Call to Action; 2019.
https://www.world-heart-federation.org/wp-content/uploads/2019/09/Improving-Access-to-Essential-Medicines-for-Circulatory-Diseases-WEB.pdf .
DOI: https://doi.org/10.5334/gh.774 | Journal eISSN: 2211-8179
Language: English
Submitted on: Feb 19, 2020
Accepted on: Sep 4, 2020
Published on: Oct 6, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2020 Mariachiara Di Cesare, Jordan D. Jarvis, Oana Scarlatescu, Xinyi Leng, Ezequiel J. Zaidel, Esteban Burrone, Jean-Luc Eiselé, Dorairaj Prabhakaran, Karen Sliwa, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.